Carlo Belloni
University of Milan
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Carlo Belloni.
European Journal of Nuclear Medicine and Molecular Imaging | 1992
G. Paganelli; Carlo Belloni; Patrizia Magnani; Felicia Zito; Andrea Pasini; I. Sassi; Mario Meroni; Massimo Mariani; Mario Vignali; Antonio G. Siccardi; Ferruccio Fazio
A new method for intraperitoneal tumour targetting in ovarian cancer using biotinylated monoclonal antibodies (MoAb) and radioactive streptavidin is described. Fifteen patients with histologically documented ovarian carcinoma were injected intraperitoneally with 2 mg of biotinylated MoAb MOv18, followed 3–5 days later by 100–150 μg of indium-111 streptavidin, at the specific activity of 280–370 MBq/mg in 500 ml of normal saline. No toxicity was observed. Tumours were imaged from 2 to 48 h after radioactivity injection by recording both planar and single photon emission tomography (SPET) data. All patients underwent surgery 1–8 days later (mean 3 days) after scanning. The resected tumour and normal tissue radioactivity were measured. On the day of surgery, the tumour to normal tissue ratio was 9:1 (range 3:1–30:1) and 45:1 (range 12:1–120:1) for intra- and extraperitoneal samples, respectively. The mean tumor to blood ratio was 14:1 (range 4:1–30:1). The injected dose (i.d.) per gram of tumour was 0.112 (range 0.01–0.3) for recurrences and 0.05 for primary tumour (range 0.005–0.2). Over 24–48 h 14% i.d. (range 8–18% i.d.) was found in the urine, 14% i.d. (range 629% i.d.) in the blood and 63% i.d. (range 56–70% i.d.) was still in the peritoneal cavity. These preliminary clinical data suggest that this two-step strategy may be superior to the conventional approach (radiolabelled antibodies) for intraperitoneal radioimmunolocalization and radioimmunotherapy of ovarian cancer.
Gynecologic Oncology | 1990
G.B. Candiani; Carlo Belloni; Renato Maggi; G. Colombo; A. Frigoli; S.G. Carinelli
From January 1, 1970 to December 31, 1979, 425 cases of endometrial carcinoma, FIGO stage I, were treated at the First Department of Obstetrics and Gynecology, University of Milan. Three different surgical approaches were used: total abdominal hysterectomy with bilateral salpingo-oophorectomy and selective pelvic lymphadenectomy was performed in 245 women, total abdominal hysterectomy and bilateral salpingo-oophorectomy without pelvic lymphadenectomy in 100, and vaginal hysterectomy with bilateral salpingo-oophorectomy in 80. Five-year survival was evaluated as a function of risk factors (histological grade, depth of myometrial invasion, metastatic nodes) in the three groups of patients, and we conclude that lymphadenectomy is useful for prognostic purposes but does not confer a therapeutic benefit.
Gynecologic Oncology | 1990
Carlo Belloni; Riccardo Viganò; Alessandro Del Maschio; Sandro Sironi; G.Luca Taccagni; Mario Vignali
Correct evaluation of myometrial infiltration is essential in patients with stage I and II endometrial cancer who are candidates for hysterectomy without lymphadenectomy, if extensive infiltration of the myometrium is not present. The aim of this study was to evaluate the use of magnetic resonance imaging (MRI) to improve staging of patients with endometrial cancer. Thirty patients with histological diagnosis of endometrial cancer were studied with MRI at 1.5 T and subsequently underwent abdominal hysterectomy. The MRI results were compared with those of the histological tests. MRI was performed with a 1.5-T magnet and spin-echo (SE) technique [repetition time/echo time (msec) = 2.000/35-90]. Contiguous 4-mm sections of were obtained from the sagittal plane. Clinical staging was not confirmed in two patients who presented with cervical extension of the tumor. The overall accuracy of MRI in determining the grade of myometrial and cervical invasion was 86 and 90%, respectively.
Gynecologic Oncology | 1988
Fabio Parazzini; Giorgia Mangili; Carlo Belloni; Carlo La Vecchia; Paola Liati; Roberta Marabini
The role of anamnestic and clinical factors in defining the high group at risk of developing persistent trophoblastic disease (PTD) has been analyzed in 301 cases of hydatidiform mole. Patients age 40 or more years with AB blood, and a previous history of molar pregnancy had an elevated risk of developing PTD. The presence of various risk factors increased the frequency of PTD. However, with discriminant analysis, correct classification of outcome was obtained for only 69% of cases. Despite the magnitude of risk of PTD for women with three or more risk factors, the clinical relevance of prognostic variables in the prediction of outcome was limited by the low proportion of women classified in the low- and high-risk groups, making the identification at diagnosis of the women who could benefit of prophylactic chemotherapy extremely difficult and hence of little clinical importance.
Cancer | 1980
Renato Musumeci; Giuseppe De Palo; Umberta Conti; Rado Kenda; Costantino Mangioni; Carlo Belloni; Marco Marzi; Gaetano Bandieramonte
The results of foot lymphography in 295 patients with endometrial carcinoma observed from 1968 to 1978 at two institutions are reported. One hundred and eighty‐two were new cases, 61 were recurrences, and 52 were patients who underwent restaging diagnostic procedures without clinical evidence of disease. The incidence of lymphatic spread was correlated with the clinical stage, the pathologic stage, and the extent of recurrent disease. In fact, in the 182 new cases, at clinical stage, lymphography was positive in 8.9% of patients at Stage I, 28.6% at Stage II, 57.1% at Stage III, and 66.6% at Stage IV disease; at pathological stage, lymphography was positive in 8% of patients at Stage I, 14.8% at Stage II, 39.3% at Stage III, and 53.3% at Stage IV disease. There was lymph node involvement in 47.5% of the 61 pretreated patients. Finally, in 52 pretreated patients with no evidence of disease, the incidence of lymph node involvement was 7.7%. In new cases, metastases were found only in the pelvic nodes in 56.2% of the patients and only in the para‐aortic nodes in 9.5%; in 34.3%, both chains were simultaneously involved. The five‐year survival rate for patients at Stage I, II, and III disease with positive lymphography was 35% as compared with 73% for negative cases. In patients at Stage I and II, the difference of survival was equal to 24%. The reliability of the results is confirmed by the concordance with the data of the literature on histologic involvement, by the first radiologic‐pathologic comparison, and by the clinical course of the positive cases. Lymphography is of unquestionable value for an appropriate staging and for a correct plan of treatment.
Tumori | 1985
Fabio Parazzini; La Vecchia C; Silvia Franceschi; Pampallona S; Adriano Decarli; Giorgia Mangili; Carlo Belloni
The relation between ABO blood group, mating patterns of patient/husband blood group, and the risk of gestational trophoblastic disease was investigated in a case-control study conducted in Milan on 286 women with histologically confirmed trophoblastic disease (245 benign hydatidiform moles and 41 persistent trophoblastic disease) and 433 control subjects admitted for normal delivery to the same hospitals where cases had been identified. ABO blood groups were associated with the risk of gestational trophoblastic disease (x26 for heterogeneity = 14.46, p = 0.02). Compared to women of group O or B, women of group A and AB had an elevated relative risk (RR) of benign mole (RR = 1.4 and 2.3, respectively). The risk estimates were higher for persistent trophoblastic disease, i.e., 2.2 for women of group A and 4.8 of group AB. The tests for linear trend in risk from benign to persistent disease were statistically significant in both A and AB groups. There was a significant interaction between blood group and age, since the ABO-related risk was elevated only for women over the age of 35. When mating combinations of maternal/paternal blood groups were considered, women of group A married to males of group O had a risk estimate not substantially different than those married to group A males.
Tumori | 1988
Giorgio Bolis; Carlo Belloni; Cristina Bonazzi; Giorgia Mangili; Mauro Presti; Flavia Zanaboni; Costantino Mangioni
Between 1976 and 1985, at the Obstetrics and Gynecology Department of Milan University, a total of 309 cases of hydatidiform mole, 223 complete moles and 86 partial moles, were monitored with the assay of beta-human chorionic gonadotropin, following a postmolar biochemical surveillance program. Spontaneous remission of the disease occurred in 287 (92.9%) patients. Marker levels were undetectable in 80.4 % of cases within 60 days after evacuation of the mole and in 19.6% between 61 and 140 days. There were 22 (7.1%) patients diagnosed as having gestational trophoblastic tumors (GTT) and treated with chemotherapy: 20 were complete moles and 2 partial moles. Considering these data, the authors suggest different follow-up times for partial and complete moles and confirm the necessity of selection criteria in a diagnosis of GTT.
Tumori | 1983
Giorgio Bolis; Carlo Belloni; Franca Vergadoro; Nicoletta Colombo; Elisabetta Buratti; Costantino Mangioni
Fifty-eight consecutive patients with malignant trophoblastic tumors of gestational origin were treated at the 1st Department of Obstetrics and Gynecology of the University of Milan between 1975 and 1981. Thirty-five (60.3%) of the patients were treated with combined surgery and chemotherapy. Of these, 44.8% had genital surgery, 12% extragenital surgery, and 5.1% had emergency laparotomies. Minor surgery was done to 17.1% of the patients. Five patients (20.8 %) with tumors limited to the uterus and treated with chemotherapy only became drug-resistant, whereas 3 patients (9%) later developed lung metastases. All the patients are alive without any clinical signs of the disease. When there were metastatic tumors, the survival of the group first submitted to a « debulking » operation of the primary focus was 80%, and the survival of the group treated only with chemotherapy was 78.5%. Seven cases required extragenital surgery for the indications discussed in detail and because they had measurable HCG. Six of these had thoracotomies and one had a craniotomy. Five of the 6 patients who underwent thoracotomy (83.4%) had a complete remission. Chemotherapy remains the treatment of choice for trophoblastic tumors. Nevertheless, our data confirm that for some cases, mostly in the high risk group, complete eradication cannot be obtained with antitumor agents. Adjuvant surgery of carefully selected patients helps to save some of those who no longer respond to chemotherapy.
Tumori | 1990
Carlo Belloni; Marco Claudio Bianchi; Gabriella Colombo; Ambrogio Frigerio; Stefania Luchini; Sylvie Ménard; Paolo Pizzetti; Gian Luca Taccagni; Elda Tagliabue; Maria I. Colnaghi
Cells from 52 ascitic fluids and 28 abdominopelvic cavity washings, obtained from 46 ovarian cancer patients, 17 patients bearing malignancies of non ovarian sites and 17 patients with non-malignant ovarian diseases, were tested using 2 methods: traditional cytology and monoclonal antibody immunofluorescence. The immunologic test using the MOv18 MAb, raised against ovarian carcinoma, revealed immunoreactive cells in 83 % of the 36 cytologically positive fluids and in one of the 8 negative fluids from ovarian carcinoma patients and in 18% of the 17 fluids from patients with non-malignant ovarian disease. Forty six cytologically positive ascitic fluids from malignant patients were analyzed in order to evaluate the ability of this MAb to identify the histotype of metastatic cells. Ninety-three percent (26/28) of the effusions from non-mucinous ovarian carcinomas contained MOv18-positive cells, whereas no reactive cells were found in cytologically malignant fluids from patients with ovarian tumors of other oncotypes or with carcinomas of non-ovarian origin. The MOv18 reagent, used as an adjuvant in cytological analysis, can help in the identification of the histotype of metastatic cells of unknown origin.
British Journal of Obstetrics and Gynaecology | 2001
Andrea Pasini; Lodovico Alfieri; Carlo Belloni
A 35 year old woman with a history of 10 years infertility and regular menstrual cycles was referred to us with six week amenorrhea. A pregnancy test performed two weeks previously was positive. No assisted reproduction technique had been performed. In the past she had undergone appendicectomy and at the age of 20 years she had undergone a left salpingo-oophorectomy for a borderline malignancy of the left ovary. The woman, totally asymptomatic, underwent pelvic ultrasonography in our outpatient clinic, which demonstrated a thickened decidua without any formation suggestive of a true gestational sac and the absence of free intraperitoneal ̄uid. The beta subunit human chorionic gonadotrophin (b -hCG) level was 1890 iu/L, and 48 hours later 1824 iu/L. Dilatation and curettage was therefore performed under general anaesthesia, and histological examination of the specimen obtained did not reveal trophoblastic villi. Two days later another measurement of b -hCG indicated that a plateau had been reached (1745 iu/L), and another pelvic ultrasound scan demonstrated a left adenexal mass measuring 2cm in diameter, with a central anechoic portion. A left ectopic pregnancy was suspected, and the woman was offered the choice of pharmacological treatment with methotrexate or laparoscopic surgery. The couple opted for endoscopic surgery. A laparoscopy was therefore performed which demonstrated the absence of the left ovary and the presence of a bluish sac-like formation about 2cm in diameter at the level of insertion of the left uterine tube, completely covered by dense adhesions, with the sigmoid colon posteriorly and with the omentum anteriorly. Filmy adhesions were observed between the right uterine tube and ovary, which were divided. No free blood was present in abdomen. The blue sac was found to be a remnant of the left fallopian tube with a blind distal extremity. The tubal remnant was removed for histological examination, which con®rmed the diagnosis of left tubal pregnancy. The womans post-operative course was uneventful, and she was discharged two days after laparoscopy.
Collaboration
Dive into the Carlo Belloni's collaboration.
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
View shared research outputsFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
View shared research outputs